the effect of citalopram on negative symptoms of schizophrenia

Phase 3

Recruiting

• Conditions: Schizophrenia.; Schizophrenia, unspecified; F20.9

• Registration Number: IRCT20221025056289N1
• Lead Sponsor: Alborz University of Medical Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Patients who, based on criteria, have been diagnosed with schizophrenia and are receiving treatment by a psychiatrist in a psychiatric ward up to 3 years after diagnosis.
The minimum PANSS score should be 60 in. This score requires a minimum of 20 on the negative symptom subscale and a BPRS score of 41.
The age range of participants is between 18 and 50.

Exclusion Criteria

The tendency and decision towards suicide in the Hamilton test.
The tendency and decision towards suicide in the Hamilton test.
Individuals with a score greater than 14 based on the 17-item Hamilton Depression Rating Scale (HDRS), or meeting major depression criteria, or having a score of above 4 on all but the depression item of the PANAS.
Patients diagnosed with any type of non-schizophrenic mental disorder, especially bipolar disorder, schizoaffective disorder, and individuals with major depressive disorders that have been identified by a psychiatric interview.
In addition, patients who have received electroconvulsive therapy (ECT) in the past 2 weeks are not eligible to participate in this study. Any serious or neurological medical condition, pregnancy or lactation, pregnant women without contraception, patients with Class IV and III heart failure, drug or insulin-dependent diabetes, liver disease, or congestive heart failure are not eligible for the study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
egative symptoms in patients with chronic schizophrenia. Timepoint: In this study, negative symptoms of schizophrenia will be assessed in the beginning, 4th week and at the end of the 8th week of the clinical trial. Method of measurement: The PANSS-BPRS questionnaire and the Hamilton questionnaire.

Secondary Outcome Measures

Name	Time	Method
Positive symptoms of patient with chronic schizophrenia. Timepoint: In this study, negative symptoms of schizophrenia will be assessed in the beginning, 4th week and at the end of the 8th week of the clinical trial. Method of measurement: Diagnosis based on DSM-5 criteria, PANSS-BPRS questionnaire.